The role of platelets in transient ischemic attacks and cerebral vascular accidents.
In a 5 1/2-year study in 585 patients, aspirin, 1200 mg/day, reduced 50% the risk of stroke or death in men who had experienced at least one episode of neurological disability in carotid or vertebral-basilar territory. Adding sulfinpyrazone to aspirin did not improve the results, and sulfinpyrazone alone was no better than placebo. Women did not experience the same benefit; aspirin did not reduce their risk of stroke or death.
D001241:Aspirin / Q000627:therapeutic use; D001792:Blood Platelets; D002561:Cerebrovascular Disorders / Q000097:blood* / Q000188:drug therapy; D005260:Female; D006801:Humans; D002546:Ischemic Attack, Transient / Q000097:blood* / Q000188:drug therapy; D008297:Male; D010919:Placebos; D013442:Sulfinpyrazone / Q000627:therapeutic use
D010919:Placebos; D001241:Aspirin; D013442:Sulfinpyrazone